Mitsubishi Tanabe Ph (MTZXF) 18.5000 $MTZXF Global

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mitsubishi Tanabe Ph (MTZXF) 18.5000 $MTZXF

Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 315.96 (+1.40), UTHR: 125.27 (-0.21), CTIC: 0.36 (-0.01), CHRS: 29.12 (+1.03), JNJ: 124.24 (+0.38), NPSP: 45.97 (+0.01), IBIO: 0.69 (unch), EBS: 29.78 (-0.91), SLXP: 172.96 (+0.15), AMGN: 173.66 (+0.99), SPPI: 7.10 (+0.07), LLY: 81.56 (-0.86), GSK: 44.89 (-0.19), ANIK: 48.91 (+0.80), NVO: 49.87 (-5.33), BAX: 48.06 (-0.02), MRK: 63.86 (+6.02), NVS: 83.12 (+0.22)

Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
BusinessWire - Wed Oct 21, 6:30AM CDT
--First patient enrolled in aducanumab Phase 3 studies for Alzheimer's disease
BIIB: 315.96 (+1.40)

Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 31.51 (-0.84), IMMU: 2.99 (+0.15), AMGN: 173.66 (+0.99), GSK: 44.89 (-0.19), BMY: 63.28 (-12.04), JNJ: 124.24 (+0.38), ARGS: 4.76 (-0.23), ANTH: 3.17 (-0.08), ABBV: 66.54 (+0.44), CBMG: 14.88 (-0.07), KPTI: 6.92 (+0.12), CELGZ: 1.11 (+0.01)

Global Secondary Hyperparathyroidism Pipeline Review 2015 - 5 Companies & 13 Drug Profiles
M2 - Mon Oct 05, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bsvf9t/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Deltanoid Pharmaceuticals Inc. - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - OPKO Health, Inc. Drug Profiles - Calcifediol MR - Calcimimetic-18 - CTA-091 - CTAP-201 - DP-001 - Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Cancer - etelcalcetide - lunacalcipol - MT-4580 - NKTR-228 - VS-105 - VS-110 - VS-411 For more information visit http://www.researchandmarkets.com/research/bsvf9t/secondary
OPK: 10.11 (+0.14), AMGN: 173.66 (+0.99), NKTR: 17.58 (+0.12)

Spinal Cord Injury - Pipeline Review H2 2015
M2 - Fri Oct 02, 5:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42rsjm/spinal_cord) has announced the addition of the "Spinal Cord Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Asubio Pharma Co., Ltd. - Athersys, Inc. - Axerion Therapeutics, Inc. - BioArctic Neuroscience AB - Cortex Pharmaceuticals, Inc. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - Genervon Biopharmaceuticals, LLC - Grupo Ferrer Internacional, S.A. - Hemostemix Ltd - Histocell S.L. - K-Stemcell Co., Ltd. - Kadimastem Ltd. - Kringle Pharma, Inc. - Lipopharma Therapeutics SL - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuronax SAS - Omeros Corporation - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Q Therapeutics, Inc. - Quark Pharmaceuticals, Inc. - Remedy Pharmaceuticals, Inc. - RhinoCyte, Inc. - SanBio, Inc. - Sirnaomics, Inc. - StemCells, Inc. - Stemedica Cell Technologies, Inc. - TissueGene, Inc. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/42...pinal_cord
VRTX: 102.43 (+2.15), ATHX: 2.14 (+0.05), ACOR: 24.72 (-0.27), LPTN: 2.05 (+0.01), OMER: 12.50 (+0.28), CUR: 0.22 (+0.01)

Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
PR Newswire - Thu Oct 01, 3:05PM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration with Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (MTPC) providing MTPC with exclusive development and commercial rights to fasinumab (REGN475), Regeneron's NGF antibody in late-stage development for musculoskeletal pain. Under the terms of the agreement, MTPC will obtain exclusive development and commercial rights to fasinumab in Japan, Korea and nine other Asian countries, excluding China.
REGN: 423.00 (-10.40)

Cardiome and Mitsubishi Tanabe Pharma Europe signs co-promotion agreement in the UK for AGGRASTAT and EXEMBOL
M2 - Thu Oct 01, 4:04AM CDT
Pharmaceutical company Cardiome Pharma (NASDAQ:CRME)(TSX:COM) revealed on Wednesday the launch of an agreement to co-promote AGGRASTAT (tirofiban HCL) and EXEMBOL (argatroban monohydrate) in the UK for an undisclosed value.
CRME: 3.06 (-0.09), COM.TO: 4.05 (-0.05)

Cardiome and Mitsubishi Tanabe Pharma Europe Enter Into an AGGRASTAT and EXEMBOL Co-Promotion Agreement in the UK
PR Newswire - Wed Sep 30, 7:00AM CDT
NASDAQ: CRME TSX: COM
CRME: 3.06 (-0.09), COM.TO: 4.05 (-0.05)

Biogen Licenses Mitsubishi Tanabe Pharma's Phase 2 Molecule for Autoimmune Diseases
BusinessWire - Wed Sep 09, 2:26AM CDT
--Mitsubishi Tanabe Pharma to receive $60 million Upfront with Potential Milestone Payments and Royalties
BIIB: 315.96 (+1.40)

Chronic Plaque Psoriasis Pipeline Review 2015 - 17 Companies & 23 Drug Profiles
M2 - Tue Sep 08, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/clbhgf/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbGenomics International, Inc. - Almirall, S.A. - Boehringer Ingelheim GmbH - Cellceutix Corporation - Coherus BioSciences, Inc. - Eli Lilly and Company - GlaxoSmithKline Plc - Johnson & Johnson - Mitsubishi Tanabe Pharma Corporation - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz International GmbH - Sun Pharma Advanced Research Company Ltd. - Takeda Pharmaceutical Company Limited - UCB S.A. - XenoPort, Inc. Drug Profiles - AbGn-168H - adalimumab biosimilar - adalimumab biosimilar - baricitinib - BI-655066 - C-82 - certolizumab pegol - CJM-112 - COVA-322 - dimethyl fumarate - etanercept biosimilar - etanercept biosimilar - etanercept biosimilar - GSK-2831781 - ixekizumab - KM-133 - lunacalcipol - MT-1303 - namilumab - orilotimod potassium - tildrakizumab - tofacitinib - XP-23829 For more information visit http://www.researchandmarkets.com/research/cl...nic_plaque
JNJ: 124.24 (+0.38), OPK: 10.11 (+0.14), PFE: 35.44 (+0.29), LLY: 81.56 (-0.86), GSK: 44.89 (-0.19), XNPT: 7.07 (+0.05), NVS: 83.12 (+0.22), CHRS: 29.12 (+1.03)

Global Peripheral Neuropathy (Sensory Neuropathy) Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Sep 08, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/32f36p/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - GeNeuro SA - INSYS Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuren Pharmaceuticals Limited - Pfizer Inc. - Polyneuron Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - Teijin Pharma Limited Drug Profiles - (immune globulin (human) hyaluronidase (recombinant)) - Cannabidiol - fingolimod hydrochloride - GL-2045 - immune globulin (human) - immune globulin (human) - LUNAR-102 - Monoclonal Antibody for CIDP - NNZ-2591 - Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - PN-1007 - Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - RGN-352 - Synthetic Peptides for Peripheral Neuropathy For more information visit http://www.researchandmarkets.com/research/32f36p/peripheral
INSY: 17.62 (+0.32), PFE: 35.44 (+0.29)

Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.56 (-0.03), APRI: 0.31 (-0.05), ACOR: 24.72 (-0.27)

Investigation Report on China's Pranoprofen Market, 2010-2019
PR Newswire Europe - Fri Aug 28, 1:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4hwkk/investigation [http://www.researchandmarkets.com/research/r4hwkk/investigation]) has announced the addition of the "Investigation Report on China's Pranoprofen Market, 2010-2019" [http://www.researchandmarkets.com/research/r4hwkk/investigation] report to their offering.

Research and Markets: Investigation Report on China's Pranoprofen Market, 2010-2019
BusinessWire - Fri Aug 28, 10:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dqfws4/investigation) has announced the addition of the "Investigation Report on China's Pranoprofen Market, 2010-2019" report to their offering.

Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 24.72 (-0.27), CVD: 106.42 (-0.71), JNJ: 124.24 (+0.38), ABBV: 66.54 (+0.44), ABT: 45.26 (+0.45), CBSTZ: 0.06 (unch), IMGN: 3.11 (+0.25), AMGN: 173.66 (+0.99), BMY: 63.28 (-12.04), GRFS: 16.57 (+0.12), GILD: 80.41 (+0.64), BAX: 48.06 (-0.02), AZN: 34.28 (-0.02), MRK: 63.86 (+6.02), NVS: 83.12 (+0.22), CELGZ: 1.11 (+0.01)

Systemic Lupus Erythematosus: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2p7pm/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects Companies Mentioned - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kymab Limited - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - National Pharmaceutical Corp. - Neovacs SA - Nippon Chemiphar Co., Ltd. - Padlock Therapeutics, Inc. - Pfizer Inc. - Plexxikon Inc. - RedHill Biopharma Ltd. - Redx Pharma Ltd - Resolve Therapeutics, LLC - Sanofi - Sarepta Therapeutics, Inc. - SATT Conectus Alsace SAS - SBI Biotech Co., Ltd. - Seattle Genetics, Inc. - Takeda Pharmaceutical Company Limited - Therapix Biosciences Ltd - UCB S.A. - Xencor, Inc. - XTL Biopharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/c2...emic_lupus
RDHL: 16.07 (-0.22), JNJ: 124.24 (+0.38), ANTH: 3.17 (-0.08), SRPT: 26.36 (-0.44), ABBV: 66.54 (+0.44), XNCR: 22.44 (+0.94), CBMG: 14.88 (-0.07), MGNX: 31.51 (-0.84), IMMU: 2.99 (+0.15), PFE: 35.44 (+0.29), AMGN: 173.66 (+0.99), BMY: 63.28 (-12.04), GSK: 44.89 (-0.19), ARGS: 4.76 (-0.23), SGEN: 47.94 (-0.09), CELGZ: 1.11 (+0.01)

Diabetes, Metabolic Syndrome and Cardiovascular Disease - 2015 Global Study
M2 - Wed Jul 22, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8qn9zj/diabetes) has announced the addition of the "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report to their offering. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease - sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes - the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles - 30 of the 65 Companies - A. Menarini - Abbott Laboratories - Abbvie - Amgen - Amylin Pharmaceuticals (bought by Bristol-Myers Squibb) - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca PLC - Bayer - Becton, Dickinson and Company - Biocon - Biodel - BodyMedia - Boehringer Ingelheim - Bristol Myers Squibb - Debiotech - DexCom - Echo Therapeutics, Inc. - Eli Lilly - FIFTY50 Medical, Inc. - Flamel Technologies - Generex Biotechnology Corporation - Lexicon Pharmaceuticals - MannKind Corporation - Medipacs - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis For more information visit http://www.researchandmarkets.com/research/8qn9zj/diabetes
ABT: 45.26 (+0.45), MDT: 87.09 (+0.33), LXRX: 16.37 (-0.14), AMGN: 173.66 (+0.99), LLY: 81.56 (-0.86), JNJ: 124.24 (+0.38), AZN: 34.28 (-0.02), MRK: 63.86 (+6.02), NVS: 83.12 (+0.22)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 323

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 259

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 297

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 609

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 494

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading

Top 5 Most Recently Viewed Articles

Unisync Triumphs at NAUMD Awards, Showcasing Innovation and Leadership

Updated Category News Views 181

Unisync Celebrates Major Recognition at NAUMD Awards Unisync Corp. (TSX: UNI) is thrilled to announce its recent achievements at the esteemed NAUMD (Network Association of Uniform Manufacturers and Distributors) Annual Convention, where it received four significant awards, showcasing its commitment to excellence in the managed uniform services industry. This remarkable...

Continue Reading
Key Economic Insights: Fed Chair Prospects and Global Data Releases

Updated Category News Views 264

Key Economic Insights for the Week Ahead The upcoming week presents a wealth of important economic information and events that could shape market expectations and financial strategies. From Federal Reserve leadership changes to significant global economic indicators, here’s what to anticipate. Potential Fed Chair Nomination With the resignation of the current Fed Chair...

Continue Reading
Understanding Investor Sentiments Surrounding AST SpaceMobile

Updated Category News Views 353

Investor Sentiment Towards AST SpaceMobile AST SpaceMobile (NYSE: ASTS) has seen a notable change in its short interest recently, with a decrease of 3.58% reported. This highlights a shift in investor sentiment, emphasizing how the market views the telecommunications innovator. Currently, approximately 45.07 million shares have been sold short, representing 20.75% of the...

Continue Reading
Insights into NuScale Power's Market Position and Trends

Updated Category News Views 163

Understanding NuScale Power's Market Sentiment NuScale Power (NYSE: SMR) has experienced notable changes in its short interest recently. The latest report indicates that the short percent of float has decreased by 6.75%, showcasing a decline in bearish sentiment towards the company. Currently, 26.80 million shares have been sold short, translating to 20.16% of all regular...

Continue Reading
BTQ Technologies and QBits Unveil Quantum-Secure Custody Infrastructure

Updated Category News Views 226

BTQ Technologies and QBits Launch Groundbreaking Initiative BTQ Technologies, in collaboration with QBits, is set to revolutionize the digital asset landscape with the development of the world's first quantum-secure custody treasury infrastructure. This partnership aims to leverage the innovative capabilities of the Quantum Canary Network, which will act as a public...

Continue Reading